Phospho-tau202 and 205 (p-tau202 and 205) antibody and antigen (Recombinant protein)

 Download 

Diagnostic Phospho-tau202 and 205 (p-tau202 and 205) antibodies (anti-Phospho-tau202 and 205, anti-p-tau202 and 205) and antigens (recombinant Phospho-tau202 and 205 (p-tau202 and 205) protein) for Neurodegenerative diseases p-tau202 and 205 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Go to Neurodegenerative diseases diagnostics products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-h-p-tau202/205-Ag01	Phospho-tau202 and 205 (p-tau202 and 205) antigen	$3090.00
GMP-h-p-tau202/205-Ab01	Anti-human p-tau202 and 205 mouse monoclonal antibody (mAb)	$1953.00
GMP-h-p-tau202/205-Ab02	Anti-human p-tau202 and 205 mouse monoclonal antibody (mAb)	$1953.00
GMP-h-p-tau202/205-Ab03	Anti-human p-tau202 and 205 human monoclonal antibody (mAb)	$1953.00
GMP-h-p-tau202/205-Ab04	Anti-human p-tau202 and 205 human monoclonal antibody (mAb)	$1953.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Pruducts	GMP-h-p-tau202/205-Ag01
Product Name	Phospho-tau202 and 205 (p-tau202 and 205) antigen
Target/Biomarker	Phospho-tau202 and 205 (p-tau202 and 205)
Alias of Target/Biomarker	DDPAC, FTDP-17L, MSTD, MTBT1, MTBT2, PPND, PPP1R103, TAU, tau-40, MAPT
Expression platform	synthesized
Isotypes	NA
Bioactivity validation	Phospho-tau202 and 205 (p-tau202 and 205) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in p-tau202 and 205 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation
Products description	Recombinant Human Phospho-tau202 and 205 (p-tau202 and 205) protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (HPLC)
Application	positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Pruducts	GMP-h-p-tau202/205-Ab01,GMP-h-p-tau202/205-Ab02
Product Name	Anti-human p-tau202 and 205 mouse monoclonal antibody (mAb)
Target/Biomarker	Phospho-tau202 and 205 (p-tau202 and 205)
Alias of Target/Biomarker	DDPAC, FTDP-17L, MSTD, MTBT1, MTBT2, PPND, PPP1R103, TAU, tau-40, MAPT
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Human Phospho-tau202 and 205 (p-tau202 and 205) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Phospho-tau202 and 205 (p-tau202 and 205) antibodies in p-tau202 and 205 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human p-tau202 and 205 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Phospho-tau202 and 205 (p-tau202 and 205) antibodies.
Reconized/Reactive Species	Human
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Pruducts	GMP-h-p-tau202/205-Ab03,GMP-h-p-tau202/205-Ab04
Product Name	Anti-human p-tau202 and 205 human monoclonal antibody (mAb)
Target/Biomarker	Phospho-tau202 and 205 (p-tau202 and 205)
Alias of Target/Biomarker	DDPAC, FTDP-17L, MSTD, MTBT1, MTBT2, PPND, PPP1R103, TAU, tau-40, MAPT
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Human Phospho-tau202 and 205 (p-tau202 and 205) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Phospho-tau202 and 205 (p-tau202 and 205) antibodies in p-tau202 and 205 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation.
Tag	hFc
Products description	Anti-human p-tau202 and 205 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Reconized/Reactive Species	Human
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Associated products

Target/Biomarker information

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by abnormal accumulation of tau protein, which plays a crucial role in maintaining the structure of nerve cells. Recent findings suggest that the phosphorylated tau fragments, such as p-tau181, p-tau217, p-tau231, and p-tau202 and 205, start to increase in the brain soon after amyloid-beta (Aβ) accumulation, years before neurofibrillary tangles are detected, and decades before symptoms appear. These markers have a larger dynamic range compared to Aβ and can distinguish AD from other forms of dementia more accurately. For instance, phosphorylated tau fragments climb up to 10-fold in blood levels as AD progresses, while the Aβ42/40 ratio falls by only about 15 percent. Monoclonal antibodies such as AT8, AT100, AT180, and AT270 have been developed to target various forms of tau protein. AT8 specifically recognizes tau phosphorylated at serine 202 and threonine 205 sites and has been used to identify abnormal tau protein accumulation in Alzheimer's disease. AT100 targets phosphorylated tau at threonine 212 and serine 214 sites, and has been shown to detect early stage neurofibrillary pathology in AD. AT180 binds to phosphorylated tau at threonine 231 site and is useful in understanding the relationship between tau protein phosphorylation and neurodegeneration. AT270 targets phosphorylated tau at threonine 181 site and has been reported to detect elevated tau protein levels in cerebrospinal fluid of AD patients. These monoclonal antibodies serve as valuable research tools for studying the pathological mechanisms underlying neurodegenerative diseases such as Alzheimer's disease.

About GDU